Business & Finance
Biotechnologies research company reports second quarter 2005 financial results
Published in Gene Therapy Weekly, August 25th, 2005
Maxygen reported a loss applicable to common stockholders of $9.9 million, or $0.28 per share, for the second quarter of 2005 compared to a loss applicable to common stockholders of $13.6 million, or $0.39 per share, in the second quarter of 2004.
As a result of the change in Maxygen's accounting for its investment in Codexis on the equity accounting basis, Maxygen does not include the operating results of Codexis in its financial statements after February 28, 2005.
Revenues in the second quarter of 2005 were $1.9 million compared to $3.6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-08-25)
More Articles from Gene Therapy Weekly
- Brain Cancer
VEGF helps transplanted neural stem cells seek brain tumors - Gene Silencing
RNA interference elicits tumor response despite hypoxia-induced VEGF-A - Gene Transfer
SART-1 gene transduction causes cellular destruction - Liver Cancer
Dynamin 2 interactions let radiation send adenoviruses into liver cells - Amyotrophic Lateral Sclerosis
Findings in amyotrophic lateral sclerosis provide new insights - Apoptosis
Hsp70 overexpression examined, effect in neonatal brain injury defined - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
